• givesomefucks@lemmy.world
    link
    fedilink
    English
    arrow-up
    2
    arrow-down
    3
    ·
    6 months ago

    Hmm. I don’t know about that. There are some areas where the US is globally a pretty major player, like pharmaceuticals

    That’s not manufacturing, it’s the research.

    And the research is only there because our shitty healthcare system is the only one that would pay for it.

    In America the poor subsidize the cost for the most cutting edge treatments only the wealthiest can afford. Pretty much the opposite of every other developed country.

    Actually making the medicine isn’t complicated, if it wasn’t for parents rival companies could make generic in a very short timeline and very low price.

    That field only does well because of friendly legislation that, you guessed it, comes from lobbying.

    It says a lot your one example of it being wrong, was a great example of me being right.

    Thanks!

        • seth@lemmy.world
          link
          fedilink
          arrow-up
          1
          arrow-down
          1
          ·
          6 months ago

          You said, it is easy and inexpensive to manufacture generics and that the expense for drug production goes into research.

          Did you not read the article you linked, or did you just not read my comment before downvoting it? It says the exact same thing in the “Controversies in FDA Bioequivalence Testing” section about the efficacy of the drug I listed as a specific example of generics not actually showing bioequivalence…TSH, free T4, and T3 in the blood are how the efficacy of levothyroxine is measured. Here, I’ll quote it for you.

          Unresolved concerns surrounding bioequivalence undermine patients’ and health care providers’ confidence in making generic substitutions. Bioequivalence studies do not assess clinical or surrogate markers that directly correlate with efficacy and/or toxicity (e.g., thyroid-stimulating hormone [TSH], seizures, transplant rejection, international normalized ratio). In addition, manufacturers do not undertake comparative studies against other generic products with the same active ingredient, yet the FDA maintains that all approved generic medications are bioequivalent